Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec; 3(12):e581-e591.

View in: PubMed

subject areas

Adult
Antineoplastic Agents
Antineoplastic Protocols
Asia
Biomarkers, Pharmacological
Bone Marrow
Comparative Effectiveness Research
Cytogenetic Analysis
Disease Progression
Drug-Related Side Effects and Adverse Reactions
Europe
Exanthema
Female
Fever
Follow-Up Studies
Headache
Hematologic Diseases
Humans
Imatinib Mesylate
Latin America
Leukemia, Myeloid, Chronic-Phase
Male
Metabolic Diseases
Middle Aged
Philadelphia Chromosome
Pyrimidines
Random Allocation
Treatment Failure

authors with profiles

JORGE E CORTES